U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H12O6
Molecular Weight 180.1559
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SCYLLO-INOSITOL

SMILES

O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O

InChI

InChIKey=CDAISMWEOUEBRE-CDRYSYESSA-N
InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3+,4+,5-,6-

HIDE SMILES / InChI
Scyllo-inositol (ELND005) is an inositol isoform. Inositol is a derivative of cyclohexane with six hydroxyl groups, making it a polyol. It also is known as a sugar alcohol, having exactly the same molecular formula as glucose or other hexoses. Scyllo-inositol (ELND005) is a naturally occurring plant sugar alcohol found most abundantly in the coconut palm. It appears to accumulate in a number of human tissues and biofluids through dietary consumption. It has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. Although scyllo-inositol (ELND005) at pharmacologic doses may alter myo-inositol levels and indirectly affect phosphatidyl-inositol signaling, its main effects are thought to be binding and inhibition of beta-amyloid 42 peptide aggregation and formation of beta-amyloid fibrils. In transgenic animals, scyllo-inositol (ELND005) reduced brain beta-amyloid concentrations and plaque burden, preserved synaptic density, and improved learning deficits. Scyllo-inositol (ELND005) also appears to neutralize toxic effects of beta-amyloid oligomers, including amelioration of oligomer-induced synaptic loss, long-term potentiation inhibition, and memory deficits. Scyllo-inositol (ELND005) is an attractive candidate as a potential disease-modifying oral treatment for Alzheimer disease.

Originator

Curator's Comment: In 1858 Staedeler and Frerichs reported the isolation of a substance from organs of the shark Scylluim canicula and the skates Raja batis and clavata which they named 'Scyllit' and described as having many similarities to the previously discovered myo-inositol. The compound was definitely related to myo-inositol by Muller in 1907 and has come to be known as scylloinositol (PMID 318234).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.7 μg/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SCYLLO-INOSITOL cerebrospinal fluid
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.5 μg/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SCYLLO-INOSITOL cerebrospinal fluid
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
39.8 μg/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SCYLLO-INOSITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17.2 μg/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SCYLLO-INOSITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
153 μg × h/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SCYLLO-INOSITOL cerebrospinal fluid
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
49.4 μg × h/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SCYLLO-INOSITOL cerebrospinal fluid
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
277 μg × h/mL
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SCYLLO-INOSITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
98.9 μg × h/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SCYLLO-INOSITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.2 h
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SCYLLO-INOSITOL cerebrospinal fluid
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
62.6 h
1000 mg 2 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SCYLLO-INOSITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Prolonged inactivation of nicotinic acid adenine dinucleotide phosphate-induced Ca2+ release mediates a spatiotemporal Ca2+ memory.
2001 Apr 6
Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor.
2001 Feb
2-Aminoethoxydiphenyl borate affects the inositol 1,4,5-trisphosphate receptor, the intracellular Ca2+ pump and the non-specific Ca2+ leak from the non-mitochondrial Ca2+ stores in permeabilized A7r5 cells.
2001 Feb
Regulation of thromboxane receptor (TP) phosphorylation by protein phosphatase 1 (PP1) and PP2A.
2001 Feb
Signaling mechanisms for the selective vasoconstrictor effect of norbormide on the rat small arteries.
2001 Feb
Requirement for Ca2+ signaling in the mechanism of thrombin-induced increase in endothelial permeability.
2001 Feb
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.
2001 Feb
Brain proton magnetic resonance spectroscopy and imaging in children exposed to cocaine in utero.
2001 Feb
Human angiotensin II type 1 receptor isoforms encoded by messenger RNA splice variants are functionally distinct.
2001 Feb
Adenosine triphosphate-evoked cytosolic calcium oscillations in human granulosa-luteal cells: role of protein kinase C.
2001 Feb
Quantitative short echo time proton magnetic resonance spectroscopic imaging study of malformations of cortical development causing epilepsy.
2001 Feb
Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus.
2001 Feb
Hydrogen peroxide induces Src family tyrosine kinase-dependent activation of Xenopus eggs.
2001 Feb
Inositol 1,4,5-trisphosphate receptor isoform expression in mouse pancreatic islets: effects of carbachol.
2001 Feb 1
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
2001 Feb 1
Nicotinic acid-adenine dinucleotide phosphate (NAADP) elicits specific microsomal Ca2+ release from mammalian cells.
2001 Feb 1
Injection of a sperm extract triggers egg activation in the newt Cynops pyrrhogaster.
2001 Feb 1
Rac and phosphatidylinositol 3-kinase regulate the protein kinase B in Fc epsilon RI signaling in RBL 2H3 mast cells.
2001 Feb 1
The endoplasmic reticulum is a glucose-modulated high-affinity sink for Ca2+ in mouse pancreatic beta-cells.
2001 Feb 1
Crucial role of type 1, but not type 3, inositol 1,4,5-trisphosphate (IP(3)) receptors in IP(3)-induced Ca(2+) release, capacitative Ca(2+) entry, and proliferation of A7r5 vascular smooth muscle cells.
2001 Feb 2
1,10-Phenanthroline inhibits glycosylphosphatidylinositol anchoring by preventing phosphoethanolamine addition to glycosylphosphatidylinositol anchor precursors.
2001 Feb 6
Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells.
2001 Feb 7
Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding and endocytosis.
2001 Feb 9
The effects of inositol treatment in animal models of psychiatric disorders.
2001 Jan
Traumatic injury of cultured astrocytes alters inositol (1,4,5)-trisphosphate-mediated signaling.
2001 Jan
Polymeric IgA binding to the human pIgR elicits intracellular signalling, but fails to stimulate pIgR-transcytosis.
2001 Jan
Novel effects of 5,8,11-eicosatriynoic acid, a lipoxygenase inhibitor, on Ca2+ mobilization in Madin Darby canine kidney cells.
2001 Jan
Saccharin activates cation conductance via inositol 1,4,5-trisphosphate production in a subset of isolated rod taste cells in the frog.
2001 Jan
Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells.
2001 Jan
Chlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cells.
2001 Jan
Intercellular Ca2+ wave propagation through gap-junctional Ca2+ diffusion: a theoretical study.
2001 Jan
An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.
2001 Jan
Expression and biological significance of Ca2+-activated ion channels in human keratinocytes.
2001 Jan
Ca(2+) mobilization, tyrosine hydroxylase activity, and signaling mechanisms in cultured porcine adrenal medullary chromaffin cells: effects of leptin.
2001 Jan
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
2001 Jan
Platelet HDL(3) binding sites are not related to integrin alpha(IIb)beta(3) (GPIIb-IIIa).
2001 Jan
PI-3 kinase and IP3 are both necessary and sufficient to mediate NT3-induced synaptic potentiation.
2001 Jan
Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry.
2001 Jan 1
Inhibitory effects of ruthenium red on inositol 1,4, 5-trisphosphate-induced responses in rat megakaryocytes.
2001 Jan 1
Structure elucidation of sphingolipids from the mycopathogen Sporothrix schenckii: identification of novel glycosylinositol phosphorylceramides with core manalpha1-->6Ins linkage.
2001 Jan 12
Endogenous glycosylphosphatidylinositol-specific phospholipase C releases renal dipeptidase from kidney proximal tubules in vitro.
2001 Jan 15
Crystal structure and catalytic mechanism of the MJ0109 gene product: a bifunctional enzyme with inositol monophosphatase and fructose 1,6-bisphosphatase activities.
2001 Jan 23
Alternative splice variants of hTrp4 differentially interact with the C-terminal portion of the inositol 1,4,5-trisphosphate receptors.
2001 Jan 5
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors.
2001 Jan 8
Desensitization of angiotensin II: effect on [Ca2+]i, inositol triphosphate, and prolactin in pituitary cells.
2001 Mar
Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes.
2001 Mar
Intracellular calcium dynamics and membrane conductance changes evoked by Deiters' cell purinoceptor activation in the organ of Corti.
2001 Mar
Multiple effects of caffeine on Ca2+ release and influx in human B lymphocytes.
2001 Mar
Inositol phosphates from barley low-phytate grain mutants analysed by metal-dye detection HPLC and NMR.
2001 Mar 1
Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor.
2001 Mar 1
Patents

Sample Use Guides

ELND005 250 mg twice daily.
Route of Administration: Oral
In toxicity assays when amyloid beta 40 was preincubated in the presence of epi- and scyllo-inositol, these mixtures increased the cell survival of PC-12 rat pheochromocytoma cells from 56 to 93% and 83%, respectively. Preincubation of amyloid beta 42 with epi- and scyllo-inositol increased cell survival from 54 to 89% and 83%, respectively. In contrast, chiro-inositol preincubation did not rescue PC-12 rat pheochromocytoma cells from either amyloid beta 40- or amyloid beta 42-induced toxicity with neuritic dystrophy similar to amyloid beta treatment alone.
Name Type Language
SCYLLO-INOSITOL
Common Name English
AZD-103
Code English
SCYLLITOL
Common Name English
SCYLLO-CYCLOHEXANEHEXOL
Common Name English
ELND005
Code English
COCOSITOL
Common Name English
ELND-005
Code English
QUERCINITOL
Common Name English
INOSITOL, SCYLLO-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1509
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
Code System Code Type Description
FDA UNII
1VS4X81277
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
CAS
488-59-5
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
NCI_THESAURUS
C122987
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
CHEBI
10642
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID50905091
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
WIKIPEDIA
SCYLLO-INOSITOL
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
EVMPD
SUB177828
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
DRUG BANK
DB03106
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY
SMS_ID
100000163522
Created by admin on Sat Dec 16 04:39:40 GMT 2023 , Edited by admin on Sat Dec 16 04:39:40 GMT 2023
PRIMARY